信隆健康(002105) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥415,025,715.79, a decrease of 35.37% compared to the same period last year[4] - Net profit attributable to shareholders was ¥62,870,572.40, down 18.99% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥54,832,112.51, a decline of 26.43% compared to the previous year[4] - The company experienced a 23.13% decline in total revenue for the first nine months of 2022, totaling ¥1,470,016,977.28[9] - Total operating revenue for the current period is ¥1,470,016,977.28, a decrease of 23.1% compared to ¥1,912,457,854.82 in the previous period[17] - Net profit for the current period is ¥205,890,796.80, a decline of 8.7% from ¥225,561,947.18 in the previous period[18] - Basic earnings per share for the current period is 0.516, compared to 0.556 in the previous period, reflecting a decrease of 7.2%[19] Assets and Liabilities - The total assets at the end of Q3 2022 were ¥1,970,861,326.33, a decrease of 13.65% from the end of the previous year[4] - The company’s total liabilities decreased by 13.65% compared to the end of the previous year[4] - Total current assets as of September 30, 2022, amount to ¥1,325,392,627.57, a decrease from ¥1,641,686,202.93 at the beginning of the year[15] - Total liabilities decreased to ¥907,363,060.64 from ¥1,338,888,575.65[16] - Long-term borrowings decreased to ¥58,438,531.82 from ¥88,998,534.44[16] Cash Flow - The cash flow from operating activities for the year-to-date was ¥206,448,259.93, an increase of 87.41% compared to the same period last year[4] - Cash flow from operating activities for the current period is ¥206,448,259.93, an increase of 87.0% from ¥110,158,422.51 in the previous period[20] - Cash flow from investing activities shows a net outflow of ¥40,723,436.96, improving from a net outflow of ¥87,598,323.25 in the previous period[21] - Cash flow from financing activities results in a net outflow of ¥200,604,289.29, compared to a smaller net outflow of ¥6,005,841.26 in the previous period[21] - The ending cash and cash equivalents balance is ¥431,808,546.64, down from ¥459,199,753.69 at the beginning of the period[21] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,865[11] - The largest shareholder, Litian Development Co., Ltd., holds 41.93% of shares, totaling 154,522,500 shares[11] - The company has no preferred shareholders among the top ten shareholders[12] Other Financial Metrics - Research and development expenses for the year-to-date were ¥43,969,187.88, a decrease of 21.67% compared to the previous year[9] - Cash and cash equivalents decreased to ¥431,808,546.64 from ¥459,199,753.69[14] - Accounts receivable decreased significantly to ¥456,237,670.13 from ¥636,496,632.73[14] - Inventory decreased to ¥320,770,164.60 from ¥435,013,849.64[15] - Total equity increased to ¥1,063,498,265.69 from ¥943,627,818.06[16] - Other comprehensive income after tax for the current period is ¥8,713,647.26, significantly higher than ¥1,227,921.29 in the previous period[18] - The company has not undergone an audit for the third quarter report[22]